Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Liedtke, 2008, Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J. Clin. Oncol., 26, 1275, 10.1200/JCO.2007.14.4147
Wicha, 2003, Prospective identification of tumorigenic breast cancer cells, Proc. Natl. Acad. Sci. USA, 100, 3983, 10.1073/pnas.0530291100
Ginestier, 2007, ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome, Cell Stem Cell, 1, 555, 10.1016/j.stem.2007.08.014
Li, 2017, Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis, Sci. Rep., 7, 13856, 10.1038/s41598-017-14364-2
Yin, H., and Glass, J. (2011). The phenotypic radiation resistance of CD44+/CD24− or low breast cancer cells is mediated through the enhanced activation of ATM signaling. PLoS ONE, 6.
Nhan, 2011, Downregulation of CD44 reduces doxorubicin resistance of CD44+ CD24− breast cancer cells, Oncotargets Ther., 4, 71
Bartucci, 2015, TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells, Oncogene, 34, 681, 10.1038/onc.2014.5
Wang, 2012, STAT3 mediates resistance of CD44+ CD24−/low breast cancer stem cells to tamoxifen in vitro, J. Biomed. Res., 26, 325, 10.7555/JBR.26.20110050
Palomeras, S., Ruiz-Martínez, S., and Puig, T. (2018). Targeting breast cancer stem cells to overcome treatment resistance. Molecules, 23.
Ma, 2014, Enriched CD44+/CD24− population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC), Cancer Lett., 353, 153, 10.1016/j.canlet.2014.06.022
Li, 2013, Stem cell marker aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast cancer, Int. J. Biol. Mark., 28, 357, 10.5301/JBM.5000048
Honeth, 2008, The CD44+/CD24− phenotype is enriched in basal-like breast tumors, Breast Cancer Res., 10, R53, 10.1186/bcr2108
Ricardo, 2011, Breast cancer stem cell markers CD44, CD24 and ALDH1: Expression distribution within intrinsic molecular subtype, J. Clin. Pathol., 64, 937, 10.1136/jcp.2011.090456
Fillmore, 2008, Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy, Breast Cancer Res., 10, R25, 10.1186/bcr1982
Tang, 2018, SOX2 promotes cell proliferation and metastasis in triple negative breast cancer, Front. Pharmacol., 9, 942, 10.3389/fphar.2018.00942
Horiuchi, 2012, MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition, J. Exp. Med., 209, 679, 10.1084/jem.20111512
Yehiely, 2006, Deconstructing the molecular portrait of basal-like breast cancer, Trends Mol. Med., 12, 537, 10.1016/j.molmed.2006.09.004
Raz, 1999, Essential role of STAT3 for embryonic stem cell pluripotency, Proc. Natl. Acad. Sci. USA, 96, 2846, 10.1073/pnas.96.6.2846
Kalluri, 2009, The basics of epithelial-mesenchymal transition, J. Clin. Investig., 119, 1420, 10.1172/JCI39104
Mani, 2008, The epithelial-mesenchymal transition generates cells with properties of stem cells, Cell, 133, 704, 10.1016/j.cell.2008.03.027
Chaffer, 2013, Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity, Cell, 154, 61, 10.1016/j.cell.2013.06.005
Yang, 2004, Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis, Cell, 117, 927, 10.1016/j.cell.2004.06.006
Thiery, 2009, Epithelial-mesenchymal transitions in development and disease, Cell, 139, 871, 10.1016/j.cell.2009.11.007
Peinado, 2007, Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?, Nat. Rev. Cancer, 7, 415, 10.1038/nrc2131
Maestro, 1999, Twist is a potential oncogene that inhibits apoptosis, Genes Dev., 13, 2207, 10.1101/gad.13.17.2207
Morel, A.-P., Lièvre, M., Thomas, C., Hinkal, G., Ansieau, S., and Puisieux, A. (2008). Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE, 3.
Karihtala, 2013, Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: Association with an aggressive tumour phenotype, Breast Cancer Res. Treat., 138, 81, 10.1007/s10549-013-2442-0
Wahl, 2017, Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity, NPJ Breast Cancer, 3, 14, 10.1038/s41523-017-0012-z
Liu, 2013, Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer, J. Surg. Oncol., 107, 188, 10.1002/jso.23240
Proia, 2011, Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate, Cell Stem Cell, 8, 149, 10.1016/j.stem.2010.12.007
Hardisson, 2008, Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype, Cancer Res., 68, 989, 10.1158/0008-5472.CAN-07-2017
Yamashita, 2013, Vimentin as a poor prognostic factor for triple-negative breast cancer, J. Cancer Res. Clin. Oncol., 139, 739, 10.1007/s00432-013-1376-6
Nalla, 2019, Self-renewal signaling pathways in breast cancer stem cells, Int. J. Biochem. Cell Biol., 107, 140, 10.1016/j.biocel.2018.12.017
Hirai, 2011, Regulation of embryonic stem cell self-renewal and pluripotency by leukaemia inhibitory factor, Biochem. J., 438, 11, 10.1042/BJ20102152
Cartwright, 2005, LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism, Development, 132, 885, 10.1242/dev.01670
Yang, 2017, MYC inhibition depletes cancer stem-like cells in triple-negative breast cancer, Cancer Res., 77, 6641, 10.1158/0008-5472.CAN-16-3452
Kim, 2013, Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells, Cell. Signal., 25, 961, 10.1016/j.cellsig.2013.01.007
Zhao, 2015, VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2, Oncogene, 34, 3107, 10.1038/onc.2014.257
Marotta, 2011, The JAK2/STAT3 signaling pathway is required for growth of CD44+ CD24–stem cell–like breast cancer cells in human tumors, J. Clin. Investig., 121, 2723, 10.1172/JCI44745
Hartman, 2013, Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8, Cancer Res., 73, 3470, 10.1158/0008-5472.CAN-12-4524-T
Tian, 2018, Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells, Br. J. Cancer, 119, 1495, 10.1038/s41416-018-0287-3
Zheng, 2011, Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival, Endocr. Relat. Cancer, 18, 491, 10.1530/ERC-11-0102
Thiagarajan, 2017, STAT3 activation by leptin receptor is essential for TNBC stem cell maintenance, Endocr. Relat. Cancer, 24, 415, 10.1530/ERC-16-0349
Creighton, 2009, Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features, Proc. Natl. Acad. Sci. USA, 106, 13820, 10.1073/pnas.0905718106
Liu, 2018, HN1L promotes triple-negative breast cancer stem cells through LEPR-STAT3 pathway, Stem Cell Rep., 10, 212, 10.1016/j.stemcr.2017.11.010
Britschgi, 2012, JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: A rationale for cotargeting these pathways in metastatic breast cancer, Cancer Cell, 22, 796, 10.1016/j.ccr.2012.10.023
Bernaciak, 2009, A novel role for signal transducer and activator of transcription 5b (STAT5b) in beta1-integrinmediated human breast cancer cell migration, Breast Cancer Res., 11, R52, 10.1186/bcr2341
Walker, 2009, Reciprocal Effects of STAT5 and STAT3 in Breast Cancer, Mol. Cancer Res., 7, 966, 10.1158/1541-7786.MCR-08-0238
Sultan, 2008, Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial–mesenchymal transition, Cancer Sci., 99, 272, 10.1111/j.1349-7006.2007.00685.x
Sultan, 2005, Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells, Oncogene, 24, 746, 10.1038/sj.onc.1208203
Tvorogov, 2009, Somatic mutations of ErbB4: Selective loss-of-function phenotype affecting signal transduction pathways in cancer, J. Biol. Chem., 284, 5582, 10.1074/jbc.M805438200
Bharadwaj, U., Kasembeli, M.M., and Tweardy, D.J. (2016). STAT3 inhibitors in cancer: A comprehensive update. STAT Inhibitors in Cancer, Springer.
Parsons, 2004, Src family kinases, key regulators of signal transduction, Oncogene, 23, 7906, 10.1038/sj.onc.1208160
Thakur, 2015, Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer, Sci. Rep., 5, 10194, 10.1038/srep10194
Kim, 2015, Radiation promotes malignant phenotypes through SRC in breast cancer cells, Cancer Sci., 106, 78, 10.1111/cas.12574
Gilani, 2016, UM-164: A potent c-Src/p38 kinase inhibitor with in vivo activity against triple-negative breast cancer, Clin. Cancer Res., 22, 5087, 10.1158/1078-0432.CCR-15-2158
Bowman, 2001, Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis, Proc. Natl. Acad. Sci. USA, 98, 7319, 10.1073/pnas.131568898
Garcia, 2001, Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells, Oncogene, 20, 2499, 10.1038/sj.onc.1204349
Herrmann, 2007, Nucleocytoplasmic shuttling of persistently activated STAT3, J. Cell Sci., 120, 3249, 10.1242/jcs.03482
Lu, 2017, Chemotherapy-Induced Ca2+ release stimulates breast cancer stem cell enrichment, Cell Rep., 18, 1946, 10.1016/j.celrep.2017.02.001
Qian, X.-L., Zhang, J., Li, P.-Z., Lang, R.-G., Li, W.-D., Sun, H., Liu, F.-F., Guo, X.-J., Gu, F., and Fu, L. (2017). Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP). PLoS ONE, 12.
Vultur, 2008, SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells, Mol. Cancer Ther., 7, 1185, 10.1158/1535-7163.MCT-08-0126
Jallal, 2007, A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo, Cancer Res., 67, 1580, 10.1158/0008-5472.CAN-06-2027
MacDonald, 2012, Frizzled and LRP5/6 receptors for Wnt/β-catenin signaling, Cold Spring Harb. Perspect. Biol., 4, a007880, 10.1101/cshperspect.a007880
Hrckulak, D., Kolar, M., Strnad, H., and Korinek, V. (2016). TCF/LEF transcription factors: An update from the internet resources. Cancers, 8.
Ring, 2014, Wnt/catenin signaling in adult stem cell physiology and disease, Stem Cell Rev. Rep., 10, 512, 10.1007/s12015-014-9515-2
Clevers, 2006, Wnt/β-catenin signaling in development and disease, Cell, 127, 469, 10.1016/j.cell.2006.10.018
De Sousa e Melo, F., and Vermeulen, L. (2016). Wnt signaling in cancer stem cell biology. Cancers, 8.
Jang, 2015, Wnt/β-catenin small-molecule inhibitor CWP232,228 preferentially inhibits the growth of breast cancer stem-like cells, Cancer Res., 75, 1691, 10.1158/0008-5472.CAN-14-2041
Jang, 2015, Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype, Sci. Rep., 5, 12465, 10.1038/srep12465
Geyer, 2011, β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation, Mod. Pathol., 24, 209, 10.1038/modpathol.2010.205
Xu, J., Prosperi, J.R., Choudhury, N., Olopade, O.I., and Goss, K.H. (2015). β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS ONE, 10.
Green, 2013, Paracrine Wnt signaling both promotes and inhibits human breast tumor growth, Proc. Natl. Acad. Sci. USA, 110, 6991, 10.1073/pnas.1303671110
Pohl, 2017, Wnt signaling in triple-negative breast cancer, Oncogenesis, 6, e310, 10.1038/oncsis.2017.14
Ring, A., Nguyen, C., Smbatyan, G., Tripathy, D., Yu, M., Press, M., Kahn, M., and Lang, J. (2018). CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer. Cancers, 10.
Corda, 2017, Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer, J. Pathol., 241, 350, 10.1002/path.4841
Yang, 2011, FZD7 has a critical role in cell proliferation in triple negative breast cancer, Oncogene, 30, 4437, 10.1038/onc.2011.145
Yin, 2013, Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer, Mol. Cancer Ther., 12, 491, 10.1158/1535-7163.MCT-12-1090
Liu, 2010, LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy, Proc. Natl. Acad. Sci. USA, 107, 5136, 10.1073/pnas.0911220107
Ma, 2017, Role of Wnt co-receptor LRP6 in triple negative breast cancer cell migration and invasion, J. Cell. Biochem., 118, 2968, 10.1002/jcb.25956
Lin, 2018, Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer, Cancer Lett., 438, 165, 10.1016/j.canlet.2018.09.022
Zhang, 2010, Wnt signaling activation and mammary gland hyperplasia in MMTV–LRP6 transgenic mice: Implication for breast cancer tumorigenesis, Oncogene, 29, 539, 10.1038/onc.2009.339
Lichtig, 2014, PTK7 modulates Wnt signaling activity via LRP6, Development, 141, 410, 10.1242/dev.095984
Gärtner, S., Gunesch, A., Knyazeva, T., Wolf, P., Högel, B., Eiermann, W., Ullrich, A., Knyazev, P., and Ataseven, B. (2014). PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvement. PLoS ONE, 9.
Ataseven, 2013, PTK7 expression in triple-negative breast cancer, Anticancer Res., 33, 3759
Damelin, 2017, A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions, Sci. Transl. Med., 9, eaag2611, 10.1126/scitranslmed.aag2611
Lenz, 2014, Safely targeting cancer stem cells via selective catenin coactivator antagonism, Cancer Sci., 105, 1087, 10.1111/cas.12471
Barrott, 2011, Deletion of mouse Porcn blocks Wnt ligand secretion and reveals an ectodermal etiology of human focal dermal hypoplasia/Goltz syndrome, Proc. Natl. Acad. Sci. USA, 108, 12752, 10.1073/pnas.1006437108
Gurney, 2012, Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors, Proc. Natl. Acad. Sci. USA, 109, 11717, 10.1073/pnas.1120068109
Aasen, 2019, Connexins in cancer: Bridging the gap to the clinic, Oncogene, 38, 4429, 10.1038/s41388-019-0741-6
Thiagarajan, 2018, Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase, Nat. Commun., 9, 578, 10.1038/s41467-018-02938-1
Qu, 2015, USP2 promotes cell migration and invasion in triple negative breast cancer cell lines, Tumor Biol., 36, 5415, 10.1007/s13277-015-3207-7
He, 2019, Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy, Cell Death Dis., 10, 285, 10.1038/s41419-019-1512-6
Davis, 2016, Small molecule inhibition of the ubiquitin-specific protease USP2 accelerates cyclin D1 degradation and leads to cell cycle arrest in colorectal cancer and mantle cell lymphoma models, J. Biol. Chem., 291, 24628, 10.1074/jbc.M116.738567
Tan, 2013, PDK1 signaling toward PLK1–MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy, Cancer Discov., 3, 1156, 10.1158/2159-8290.CD-12-0595
Popov, 2010, Ubiquitylation of the amino terminus of Myc by SCFβ-TrCP antagonizes SCFFbw7-mediated turnover, Nat. Cell Biol., 12, 973, 10.1038/ncb2104
Maire, 2013, Polo-like kinase 1: A potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer, Cancer Res., 73, 813, 10.1158/0008-5472.CAN-12-2633
Li, 2019, Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer, Oncol. Rep., 41, 437
Stover, 2018, Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple negative breast cancer, NPJ Breast Cancer, 4, 10, 10.1038/s41523-018-0060-z
Hirpara, J., Eu, J.Q., Tan, J.K.M., Wong, A.L., Clement, M.-V., Kong, L.R., Ohi, N., Tsunoda, T., Qu, J., and Goh, B.C. (2018). Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance. Redox Biol., 101076.
Wong, 2015, Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies, Ann. Oncol., 26, 998, 10.1093/annonc/mdv026
Hong, 2015, AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer, Sci. Transl. Med., 7, 314ra185, 10.1126/scitranslmed.aac5272
Xu, X., Kasembeli, M.M., Jiang, X., Tweardy, B.J., and Tweardy, D.J. (2009). Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS ONE, 4.
Arensman, 2014, The CREB binding protein inhibitor ICG-001 suppresses pancreatic cancer growth, Mol. Cancer Ther., 13, 2303, 10.1158/1535-7163.MCT-13-1005
Ko, 2016, Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX, J. Clin. Oncol., 34, e315721, 10.1200/JCO.2016.34.15_suppl.e15721
Solzak, 2017, Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer, NPJ Breast Cancer, 3, 17, 10.1038/s41523-017-0016-8
Zhang, 2017, Discovery of novel frizzled-7 inhibitors by targeting the receptor’s transmembrane domain, Oncotarget, 8, 91459, 10.18632/oncotarget.20665
Nickho, 2017, Developing and characterization of single chain variable fragment (scFv) antibody against frizzled 7 (Fzd7) receptor, Bioengineered, 8, 501, 10.1080/21655979.2016.1255383
Zarei, 2018, Cell growth inhibition and apoptosis in breast cancer cells induced by anti-FZD7 scfvs: Involvement of bioinformatics-based design of novel epitopes, Breast Cancer Res. Treat., 169, 427, 10.1007/s10549-017-4641-6
Mita, 2016, Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with paclitaxel (P) in patients (pts) with 1st- to 3rd-line metastatic HER2-negative breast cancer (BC), J. Clin. Oncol., 34, 2516, 10.1200/JCO.2016.34.15_suppl.2516
Blay, 2010, Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network of Core Institutes (NOCI), Eur. J. Cancer, 46, 2206, 10.1016/j.ejca.2010.03.039
Sancho, 2016, Hallmarks of cancer stem cell metabolism, Br. J. Cancer, 114, 1305, 10.1038/bjc.2016.152
Shen, 2015, Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP, Proc. Natl. Acad. Sci. USA, 112, 5425, 10.1073/pnas.1501555112
Carracedo, 2013, Cancer metabolism: Fatty acid oxidation in the limelight, Nat. Rev. Cancer, 13, 227, 10.1038/nrc3483
Camarda, 2016, Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer, Nat. Med., 22, 427, 10.1038/nm.4055
Wang, 2018, JAK/STAT3-regulated fatty acid β-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance, Cell Metab., 27, 136, 10.1016/j.cmet.2017.11.001
Hammoudi, 2011, Metabolic alterations in cancer cells and therapeutic implications, Chin. J. Cancer, 30, 508, 10.5732/cjc.011.10267
Palorini, 2014, Energy Metabolism Characterization of a Novel Cancer Stem Cell-L ike Line 3 AB-OS, J. Cell. Biochem., 115, 368, 10.1002/jcb.24671
Pecqueur, 2013, Targeting metabolism to induce cell death in cancer cells and cancer stem cells, Int. J. Cell Biol., 2013, 805975, 10.1155/2013/805975
Ciavardelli, 2014, Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment, Cell Death Dis., 5, e1336, 10.1038/cddis.2014.285
Luo, 2018, Targeting breast cancer stem cell state equilibrium through modulation of redox signaling, Cell Metab., 28, 69, 10.1016/j.cmet.2018.06.006
Colegio, 2014, Functional polarization of tumour-associated macrophages by tumour-derived lactic acid, Nature, 513, 559, 10.1038/nature13490
Mu, 2018, Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer, Cell Cycle, 17, 428, 10.1080/15384101.2018.1444305
Cascone, 2018, Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy, Cell Metab., 27, 977, 10.1016/j.cmet.2018.02.024
Sugiura, 2018, Metabolic barriers to T cell function in tumors, J. Immunol., 200, 400, 10.4049/jimmunol.1701041
Pelicano, 2014, Mitochondrial dysfunction in some triple-negative breast cancer cell lines: Role of mTOR pathway and therapeutic potential, Breast Cancer Res., 16, 434, 10.1186/s13058-014-0434-6
Lim, 2016, EGFR signaling enhances aerobic glycolysis in triple-negative breast cancer cells to promote tumor growth and immune escape, Cancer Res., 76, 1284, 10.1158/0008-5472.CAN-15-2478
Dombrauckas, 2005, Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis, Biochemistry, 44, 9417, 10.1021/bi0474923
Mazurek, 2005, Pyruvate kinase type M2 and its role in tumor growth and spreading, Semin. Cancer Biol., 15, 300, 10.1016/j.semcancer.2005.04.009
Christofk, 2008, The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth, Nature, 452, 230, 10.1038/nature06734
Dong, 2013, Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer, Cancer Cell, 23, 316, 10.1016/j.ccr.2013.01.022
Peng, 2018, Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia, Oncogene, 37, 1062, 10.1038/onc.2017.368
Howell, 2017, Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex, Cell Metab., 25, 463, 10.1016/j.cmet.2016.12.009
Kalender, 2010, Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner, Cell Metab., 11, 390, 10.1016/j.cmet.2010.03.014
Salani, 2014, Metformin, cancer and glucose metabolism, Endocr. Relat. Cancer, 21, R461, 10.1530/ERC-14-0284
Edgerton, 2018, Metformin targets glucose metabolism in triple negative breast cancer, J. Oncol. Transl. Res., 4, 129
Salani, 2013, Metformin impairs glucose consumption and survival in Calu-1 cells by direct inhibition of hexokinase-II, Sci. Rep., 3, 2070, 10.1038/srep02070
Koh, 2013, A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells, Bioorg. Med. Chem., 21, 2305, 10.1016/j.bmc.2013.02.015
Li, 2017, Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2, J. Exp. Clin. Cancer Res., 36, 58, 10.1186/s13046-017-0530-4
Ho, 2015, Pyruvate dehydrogenase kinase expression and metabolic changes following dichloroacetate exposure in anoxic human colorectal cancer cells, Exp. Cell Res., 331, 73, 10.1016/j.yexcr.2014.12.006
Sun, 2010, Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo, Breast Cancer Res. Treat., 120, 253, 10.1007/s10549-009-0435-9
Ruggieri, 2015, Dichloroacetate, a selective mitochondria-targeting drug for oral squamous cell carcinoma: A metabolic perspective of treatment, Oncotarget, 6, 1217, 10.18632/oncotarget.2721
Jia, D., Park, J., Jung, K., Levine, H., and Kaipparettu, B. (2018). Elucidating the metabolic plasticity of cancer: Mitochondrial reprogramming and hybrid metabolic states. Cells, 7.
Lee, 2017, MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation, Cell Metab., 26, 633, 10.1016/j.cmet.2017.09.009
Bhola, 2016, Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and notch-dependent cancer stem cell population, Cancer Res., 76, 440, 10.1158/0008-5472.CAN-15-1640-T
Molina, 2018, An inhibitor of oxidative phosphorylation exploits cancer vulnerability, Nat. Med., 24, 1036, 10.1038/s41591-018-0052-4
Deribe, 2018, Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer, Nat. Med., 24, 1047, 10.1038/s41591-018-0019-5
Wright, 2017, CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation, Proc. Natl. Acad. Sci. USA, 114, E6556, 10.1073/pnas.1703791114
Holubarsch, 2007, A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: The ERGO (etomoxir for the recovery of glucose oxidation) study, Clin. Sci., 113, 205, 10.1042/CS20060307
Crawford, 2016, A tyrosine-reactive irreversible inhibitor for glutathione S-transferase Pi (GSTP1), Mol. Biosyst., 12, 1768, 10.1039/C6MB00250A
Louie, 2016, GSTP1 is a driver of triple-negative breast cancer cell metabolism and pathogenicity, Cell Chem. Biol., 23, 567, 10.1016/j.chembiol.2016.03.017
Shi, 2017, Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation, Cell Discov., 3, 17010, 10.1038/celldisc.2017.10
Erchegyi, 1996, A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity, Proc. Natl. Acad. Sci. USA, 93, 12513, 10.1073/pnas.93.22.12513
Butler, 2013, Stalling the engine of resistance: Targeting cancer metabolism to overcome therapeutic resistance, Cancer Res., 73, 2709, 10.1158/0008-5472.CAN-12-3009
Weng, 2008, Sensitizing estrogen receptor–negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor, Mol. Cancer Ther., 7, 800, 10.1158/1535-7163.MCT-07-0434
Feldman, 2005, Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1, J. Biol. Chem., 280, 19867, 10.1074/jbc.M501367200
Lim, 2015, Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: Ubiquinone oxidoreductase (Complex I), Am. J. Cancer Res., 5, 689
Navarro, 2016, Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics, Cell Rep., 15, 2705, 10.1016/j.celrep.2016.05.052
Christenson, 2017, MMTV-PyMT and derived Met-1 mouse mammary tumor cells as models for studying the role of the androgen receptor in triple-negative breast cancer progression, Horm. Cancer, 8, 69, 10.1007/s12672-017-0285-6